¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦17ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö : 2022-04-08

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦17ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö : 2022-04-08
±³À°ÀÏÀÚ : 2022-04-08
±³À°Àå¼Ò : °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ(HICO)  
±³À°ÁÖÁ¦ : Á¦17ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
´ã´çÀÚ : ±è¹Ì¼±
¿¬¶ôó : 02-575-3825  
À̸ÞÀÏ : katrd@hanmail.net      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í »çÀüµî·Ï : Àü¹®ÀÇ, ÀϹÝÀÇ 30,000¿ø / Àü°øÀÇ, ±âŸ 20,000¿ø ÇöÀåµî·Ï : Àü¹®ÀÇ, ÀϹÝÀÇ 40,000 / Àü°øÀÇ, ±âŸ 30,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-08 3F 12:40~13:40 ¡°Antifibrotic Therapy in Fibrosing ILD : Lessons from 10 Years of Experience¡±  ¼ÛÁø¿ì(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04-08 3F 14:10~14:40 1. Impact of Exercise and Nutrition on the Immune System and Outcomes in NSCLC  ¹ÚÁøÇÑ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 04-08 3F 14:40~15:10 2. Lung Cancer Treatment in COVID-19 Era  °­´ÙÇö(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04-08 3F 15:10~15:40 3. The Problematic Cases of Pathologic Diagnosis with Suspected Lung Cancer  ¾öÁß¼·(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04-08 3F 16:00~16:30 4. Newly Approved Targeted Agents  ÀÌ»óÈÆ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-08 3F 16:30~17:00 5. Advanced Adjuvant Therapy in NSCLC  ÀÓÁ¤¿í(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-08 3F 17:00~17:30 6. Not Common But, Essential Adverse Events in Patients Being Treated with ICIs  À̽ÂÇö(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-08 3F 17:30~18:10 ¡°Optimal therapy for treatment in all severity of Asthma¡°  ±èÁø¿ì(°¡Å縯ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦17ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö : 2022-04-08""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ 2022³âµµ Á¦2Â÷ Interactive Learning : 2022-04-08
´ÙÀ½±Û 2022³âµµ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-04-08
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20946 °­¿ø ÀÌ»óÁöÁúÇ÷Áõ Ä¡·á ¹× º¸Çè½É»çÀ̽´¿¡ ´ëÇÑ ÃÖ½ÅÁö°ß : 2024-06-17 0 0 15:09:31
20945 ¼­¿ï 2024³â ´ëÇÑ¿©¼º¼ºÀÇÇÐȸ Á¦17ȸ Ãá°èÇмú´ëȸ : 2024-06-16 0 0 15:05:04
20944 ¼­¿ï Á¦28ȸ ¼­¿ï½Ã³»°úÀÇ»çȸ Á¤±âÃÑȸ ¹× Çмú´ëȸ : 2024-06-16 0 0 15:02:37
20943 ´ë±¸ Á¦22Â÷ ´ë°æÇǺÎÄ¡·áÇмú´ëȸ : 2024-06-16 0 0 15:00:35
20942 ¼­¿ï ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ (¿Â¶óÀÎ) Á¦ 5ȸ ¼Ò¾Æ ÁøÁ¤ ±âº» ¿öÅ©¼ó : 2024-06-16 0 0 14:59:12
20941 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Cervical Cancer Screening and Colposcopy Educational Course: General Course : 2024-06-16 0 0 14:57:48
20940 ÀÎõ ÀÎõ±¤¿ª½ÃÀÇ»çȸ 2024 Á¾ÇÕÇмú´ëȸ : 2024-06-16 0 0 14:56:27
20939 ¼­¿ï (¿Â¶óÀÎ) 2024³â 2ºÐ±â °Ëü°Ë»çÁú°¡»ê¼ö°¡ Àü¹®Àη¿µ¿ª ½Å±Ô±³À°_¹«Æò : 2024-06-16 0 0 14:55:04
20938 ´ë±¸ 2024³â Á¦3ȸ ´ë±¸°æºÏ³ëÀÎÀÇÇÐȸ ¿¬¼ö°­Á : 2024-06-16 0 0 14:53:47
20937 ´ë±¸ Á¦24Â÷ ´ëÇѼҾƽÉÀåÇÐȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 0 14:52:29
20936 ÀÎõ 2024³â ´ëÇѵΰæºÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 0 14:48:46
20935 ¼­¿ï ´ëÇѽɺÎÀüÇÐȸ 2024 ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-15 0 0 14:44:25
20934 Á¦ÁÖ ´ëÇѸðüžÆÀÇÇÐȸ Á¦30Â÷ Çмú´ëȸ : 2024-06-15 0 0 14:43:02
20933 Á¦ÁÖ È£³²½½°üÀý¿¬±¸È¸ Á¦76Â÷ Áý´ãȸ : 2024-06-15 0 0 14:41:46
20932 ¼­¿ï VESC 2024 Ç÷°ü¿Ü°ú Ç÷°ü½Ã¼ú ÄÁÆÛ·±½º (Vascular Endovascular Surgery Conference) : 2024-06-15 0 0 14:40:31
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷